Protera S.r.l.

Bruker Biospin Gmbh

Università Degli Studi Di Trento

Claudio Luchinat

Ivano Bertini

Marco Fragai

Leonardo Manzoni

Pierfausto Seneci

Alessandro Quattrone

Cristina Nativi

Luciana Marinelli

Ettore Novellino

Alessandro Mordini

Chiara Venturi

Vito Giuseppe D'Agostino

Preet Lal

Linda Cerofolini

Massimo Calamante

Chiara Zucal

Mauro Lo Conte

Carmelo Fuccio

Alessandro Provenzani

Natthakan Thongon

Valentina Adami

Panteleimon Takis

Object of the present invention are new aza-tanshinone derivatives, a method for their preparation and their use in therapy, particularly, but not limited to, as anti-tumor agents and anti-inflammatories. The invention comprises also the pharmaceutical compositions containing them.

Aza-tanshinone derivatives, process for their preparation and their use in therapy

Correlation information between captured characteristics and chemical shift values of captured NMR spin systems is provided by a model appliance for a fluid class. An NMR spectrum of a sample of the fluid class is recorded. Peaks in the recorded NMR spectrum which belong to defined reference NMR spin systems are identified, and experimental chemical shift values of the peaks from the recorded NMR spectrum are determined. A chemical shift value of at least one of the captured NMR spin systems not belonging to the reference NMR spin systems is predicted by applying the model appliance onto the experimental chemical shift values of the reference NMR spin systems. Peaks in an NMR spectrum of a sample of a fluid class are attributed more quickly and reliably to NMR spins systems of compounds contained in the sample.

Method for predicting chemical shift values of NMR spin systems in a sample of a fluid class, in particular in a sample of a biofluid

The invention provides prodrugs activated by RNA-dependent DNA-polymerases, and methods for treating hematological tumors, blood, and blood derivatives from patients affected by retroviral infections by administering the prodrugs. The invention also provides methods for the preparation of pharmaceutical compositions containing the prodrugs.

Prodrugs activated by RNA-dependent DNA-polymerases

Described herein are derivatives of arylsulfonamido-substituted hydroxamic acid of formula (I) having good solubility in water and inhibitory activity of matrix metalloproteinases, useful for the preparation of pharmaceutical compositions for the treatment of diseases associated to a pathologic activity and/or an over-expression of metalloproteinases, and of cosmetic preparations having anti-ageing properties in particular for hair and skin. 

Derivatives of arylsulfonamido-substituted hydroxamic acid as matrix metalloproteinases inhibitors

Growing community of inventors

Florence, Italy

Claudio Luchinat